Nicola J. Curtis

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity

Nicola J. Curtis, Lorraine Mooney, Lorna Hopcroft et al. · Oncotarget · 2017 · 158 citations · Full text

Medicine, Oncology, Pharmacology +13

The ABC Transporter AnrAB Contributes to the Innate Resistance of <i>Listeria monocytogenes</i> to Nisin, Bacitracin, and Various β-Lactam Antibiotics

Barry Collins, Nicola J. Curtis, Paul D. Cotter et al. · Antimicrobial Agents and Chemotherapy · 2010 · 154 citations · Full text

Life Sciences, Microbiology, Molecular Genetics +17

Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3

Scott Boyd, Joanna Brookfield, Susan E. Critchlow et al. · Journal of Medicinal Chemistry · 2015 · 96 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles

Nicolas Floc’h, Susan Ashton, Paula Taylor et al. · Molecular Cancer Therapeutics · 2017 · 36 citations · Full text

Medicine, Oncology, Pharmacology +13

Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma

Nicolas Floc’h, Susan Ashton, Douglas Ferguson et al. · Molecular Cancer Therapeutics · 2019 · 22 citations · Full text

Medicine, Oncology, Pharmacology +17